Protective RBD-dimer vaccines against SARS-CoV-2 and its variants produced in glycoengineered Pichia pastoris
Tongxin Zhao,Sheng Liu,Pengyan Wang,Yanfang Zhang,Xinrui Kang,Xiaoqian Pan,Linjie Li,Dedong Li,Ping Gao,Yaling An,Hao Song,Kefang Liu,Jianxun Qi,Xin Zhao,Lianpan Dai,Peipei Liu,Peiyi Wang,Guizhen Wu,Taicheng Zhu,Kun Xu,Yin Li,George F. Gao
DOI: https://doi.org/10.1371/journal.ppat.1012487
IF: 7.464
2024-09-02
PLoS Pathogens
Abstract:Protective vaccines are crucial for preventing and controlling coronavirus disease 2019 (COVID-19). Updated vaccines are needed to confront the continuously evolving and circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. These vaccines should be safe, effective, amenable to easily scalable production, and affordable. Previously, we developed receptor binding domain (RBD) dimer-based protein subunit vaccines (ZF2001 and updated vaccines) in mammalian cells. In this study, we explored a strategy for producing RBD-dimer immunogens in Pichia pastoris . We found that wild-type P . pastoris produced hyperglycosylated RBD-dimer protein containing four N-glycosylation sites in P . pastoris . Therefore, we engineered the wild type P . pastoris (GS strain) into GSΔOCH1pAO by deleting the OCH1 gene (encoding α-1,6-mannosyltransferase enzyme) to decrease glycosylation, as well as by overexpressing the HIS4 gene (encoding histidine dehydrogenase) to increase histidine synthesis for better growth. In addition, RBD-dimer protein was truncated to remove the R328/F329 cleavage sites in P . pastoris . Several homogeneous RBD-dimer proteins were produced in the GSΔOCH1pAO strain, demonstrating the feasibility of using the P . pastoris expression system. We further resolved the cryo-EM structure of prototype-Beta RBD-dimer complexed with the neutralizing antibody CB6 to reveal the completely exposed immune epitopes of the RBDs. In a murine model, we demonstrated that the yeast-produced RBD-dimer induces robust and protective antibody responses, which is suitable for boosting immunization. This study developed the yeast system for producing SARS-CoV-2 RBD-dimer immunogens, providing a promising platform and pipeline for the future continuous updating and production of SARS-CoV-2 vaccines. SARS-CoV-2 continuously circulates, resulting in infections and re-infections globally. COVID-19 vaccines can provide protection against disease and death caused by SARS-CoV-2. However, the immune responses induced by vaccination will wane gradually. In addition, new SARS-CoV-2 sub-variants emerge and show immune evasion. Therefore, inoculating with the updated COVID-19 vaccines is recommended for enhancing protection against the circulating SARS-CoV-2 sub-variants. Pichia pastoris is an eukaryotic system that enables fast and low-cost producing proteins with easy scale-up. In this study, we developed a strategy for producing SARS-CoV-2 RBD-dimer immunogens in glycoengineered Pichia pastoris with homogeneous glycosylation and high stability. The RBD antigen can be updated with the sequence of circulating sub-variants. In addition, mouse experiments demonstrated that the yeast-produced RBD-dimer vaccines induced robust and protective immune responses. This study provides a simple and promising approach to produce yeast-derived SARS-CoV-2 RBD-dimers as a boosting vaccine and guides the basis for the production of the other vaccines in Pichia pastoris .
microbiology,virology,parasitology